New entrants to multiple sclerosis market will drive 10% pa growth through 2018 The Pharma Letter ... reformulations of platform injectables and three highly efficacious monoclonal antibodies - Genzyme/Bayer's (BAYN: DE) Lemtrada (alemtuzumab), Roche (ROG: SIX)/Genentech's ocrelizumab and Biogen Idec/AbbVie's (NYSE: ABBV) daclizumab. |
